Thursday, 5 May 2011

Keryx says more European drug trials not necessary

Keryx Biopharmaceuticals says that it does not believe that it will need to carry out more tests so that its kidney drug Zerenex (ferric citrate) will be approved in Europe. This was reported on several news sites.

The drug is used to treat high phosphate levels (hyperphosphatemia) in patients with chronic kidney disease as well as those on dialysis. The drug is already licensed in many other markets, apart from some Asian areas.

Volunteers for trials were recruited around October 2010. A report in December 2010 said that it successfully reduced phosphate levels.